116 related articles for article (PubMed ID: 34632169)
1. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
[TBL] [Abstract][Full Text] [Related]
2. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
[TBL] [Abstract][Full Text] [Related]
3. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
4. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
5. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
Chow RD; Long JB; Hassan S; Wheeler SB; Spees LP; Leapman MS; Hurwitz ME; McManus HD; Gross CP; Dinan MA
JNCI Cancer Spectr; 2023 May; 7(3):. PubMed ID: 37202354
[TBL] [Abstract][Full Text] [Related]
6. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
Dzimitrowicz HE; Wilson LE; Jackson BE; Spees LP; Baggett CD; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman MS; Gross CP; Dinan MA; Wheeler SB
JCO Oncol Pract; 2023 Feb; 19(2):e213-e227. PubMed ID: 36413741
[TBL] [Abstract][Full Text] [Related]
7. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
[TBL] [Abstract][Full Text] [Related]
8. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
10. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.
Miller SM; Wilson LE; Greiner MA; Pritchard JE; Zhang T; Kaye DR; Cohen HJ; Becher RD; Maerz LL; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):635-643. PubMed ID: 34996724
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
15. Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.
Leong C; Czaykowski P; Geirnaert M; Katz A; Dragan R; Yogendran M; Raymond C
Can J Public Health; 2021 Jun; 112(3):530-540. PubMed ID: 33471346
[TBL] [Abstract][Full Text] [Related]
16. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
[TBL] [Abstract][Full Text] [Related]
18. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
19. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
20. INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION.
Dinan MA; Li Y; Reed SD; Sosa JA
Endocr Pract; 2019 Jan; 25(1):31-42. PubMed ID: 30383499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
